Novartis AG (NVS)

NYSE - NYSE Real Time Price. Currency in USD
78.96-0.29 (-0.37%)
At close: 4:02 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close79.25
Bid78.37 x 100
Ask81.60 x 100
Day's Range78.28 - 79.14
52wk Range69.90 - 95.11
1y Target EstN/A
Market Cap187.37B
P/E Ratio (ttm)28.19
Avg Vol (3m)1,329,334
Dividend & Yield2.72 (3.43%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Reuters10 hours ago

    Novartis psoriasis drug maintains efficacy after 4 years - study

    Novartis's psoriasis drug Cosentyx showed long-term efficacy in keeping patients' skin clear, the Swiss drugmaker said on Saturday, citing a study it hopes will ultimately help the company to win business from rival medicines made by Amgen and Johnson & Johnson . More than 66 percent of Cosentyx patients achieved "clear or almost clear" skin after four years, Novartis said, comparable with the 68.5 percent who hit that milestone after one year. A durable response is important, since older biotech drugs for plaque psoriasis, known as anti-TNFs, can lose their effectiveness over time.

  • Prothena Builds On Psoriasis Science For Arthritis Treatment
    Investor's Business Daily19 hours ago

    Prothena Builds On Psoriasis Science For Arthritis Treatment

    Prothena said late Thursday that it plans to launch phase two testing for a psoriatic arthritis drug.

  • Investopedia2 days ago

    Amgen Maintains Migraine Drug Lead (AMGN)

    Amgen leads the migraine drug race by being the first company to publish phase 3 results, but intense competition looms in the future